Medical note: This article provides general educational information and does not replace the FDA-approved prescribing information or advice from an immunologist, pharmacist, or other qualified healthcare professional. Cuvitru dosing must be calculated and adjusted by a prescriber. Never change an infusion dose, rate, frequency, or number of infusion sites on your own.
Cuvitru is a concentrated immune globulin treatment designed for people whose immune systems do not make enough effective antibodies. Instead of being delivered into a vein at an infusion center, it is infused into fatty tissue under the skin. After proper training and several supervised treatments, many patients can administer it at home.
That flexibility can make long-term antibody replacement easier to fit around school, work, travel, and the important business of not spending every free afternoon in a medical chair. However, Cuvitru is still a powerful plasma-derived prescription product. It carries serious warnings, requires careful dose calculations, and can cause reactions ranging from temporary redness to rare medical emergencies.
What Is Cuvitru?
Cuvitru is the brand name for immune globulin subcutaneous (human), 20% solution. It contains purified immunoglobulin G, commonly called IgG, collected from pooled human plasma. IgG antibodies help the immune system recognize and respond to numerous bacteria, viruses, and other disease-causing organisms.
The product contains 200 milligrams of protein per milliliter, making it a relatively concentrated subcutaneous immune globulin, or SCIG, therapy. Glycine is used as a stabilizing and buffering ingredient. Cuvitru contains no added sugar, sodium, or preservatives and does not contain sucrose.
How Cuvitru works
People with certain primary immunodeficiencies may produce too little IgG or make antibodies that do not function properly. Cuvitru supplies working IgG antibodies from healthy donors. These antibodies do not permanently repair the underlying immune disorder, but regular replacement therapy can maintain protective antibody levels and reduce vulnerability to infections.
Because the infused antibodies are gradually used and cleared by the body, treatment must be repeated on a consistent schedule. Skipping infusions can allow IgG levels to fall, rather like forgetting to charge a battery that your immune system relies on every day.
What Is Cuvitru Used For?
Cuvitru is FDA-approved as replacement therapy for primary humoral immunodeficiency in adults and children age 2 years and older. Conditions that may fall within this indication include:
- Common variable immunodeficiency, or CVID
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich syndrome
- Severe combined immunodeficiencies
- Other primary antibody disorders for which IgG replacement is medically appropriate
Although some other subcutaneous immune globulin products have additional approved uses, Cuvitru’s U.S. indication is specifically replacement therapy for primary humoral immunodeficiency. Patients should not assume that all SCIG brands are approved for the same conditions or can be exchanged dose-for-dose without professional guidance.
Cuvitru Dosing and Administration
Cuvitru is administered only by subcutaneous infusion. It must not be injected into a vein or muscle. A healthcare professional determines the total dose, frequency, infusion rate, number of sites, needle equipment, and pump settings.
How often is Cuvitru given?
The prescribing information allows regular dosing schedules ranging from daily administration to once every two weeks. Weekly and every-other-week schedules are common, but some patients divide their weekly amount into smaller, more frequent infusions.
The best schedule depends on the patient’s previous immune globulin treatment, body weight, IgG levels, infection history, tolerability, and lifestyle. Clinical response matters more than chasing a laboratory number simply because it looks tidy on paper.
Switching from IVIG or HyQvia
When switching from intravenous immune globulin or, in eligible adults, from HyQvia, Cuvitru generally begins one week after the previous infusion. The labeled calculation for the initial weekly amount is:
Previous IVIG or HyQvia dose in grams ÷ number of weeks between doses × 1.30
For example, a person previously receiving 40 grams every four weeks would have a calculated starting amount of 13 grams weekly: 40 divided by 4, then multiplied by 1.30. Because Cuvitru contains 200 milligrams per milliliter, grams are converted to milliliters by multiplying by five. In this example, 13 grams equals 65 milliliters.
This example explains the labeled formula; it is not a personal dosing recommendation. A prescriber may adjust treatment according to serum IgG trough levels, breakthrough infections, adverse reactions, and other clinical factors.
Switching from another SCIG product
When switching from another subcutaneous immune globulin, the initial weekly Cuvitru dose in grams is generally the same as the previous weekly SCIG dose. A weekly amount may be divided across two to seven treatments per week, while every-other-week treatment generally uses twice the weekly amount.
Infusion sites and rates
Suggested infusion areas include the abdomen, thighs, upper arms, and outer hip. Sites should be rotated, positioned at least four inches apart, and kept away from scars, prominent bones, visible blood vessels, infection, or irritated skin.
Up to four sites may be used at the same time. During the first two infusions, the recommended rate is 10 to 20 milliliters per hour per site. If treatment is tolerated, later infusions may increase to as much as 60 milliliters per hour per site. With four sites, the maximum combined labeled rate is 240 milliliters per hour.
For the first two infusions, patients weighing less than 40 kilograms are generally limited to 20 milliliters at each site. Patients weighing at least 40 kilograms may receive up to 60 milliliters per site. Subsequent infusions may use up to 60 milliliters per site as tolerated.
Maximum numbers are ceilings, not goals. A slower rate, smaller site volume, or additional sites may be more comfortable for a particular patient.
How to Prepare and Use Cuvitru Safely
Patients and caregivers must receive hands-on training before attempting home infusion. Proper technique includes washing hands, preparing a clean workspace, checking each vial, using aseptic technique, priming the tubing, placing the needles correctly, and documenting the treatment.
- Inspect the solution before use.
- Do not use a cloudy or turbid solution or one containing particles.
- Do not shake or dilute Cuvitru.
- Do not mix it with another medication.
- Use each vial only once and discard the unused portion.
- Begin the infusion promptly after transferring the medicine into a syringe.
- Record the date, dose, sites, lot numbers, infusion time, and reactions.
If a dose is missed or an infusion cannot be completed, contact the prescribing team for instructions. Do not double the next dose unless specifically directed.
Common Cuvitru Side Effects
The most frequent Cuvitru side effects occur around the infusion site. These reactions are often mild or moderate and may improve as the patient gains experience with the treatment.
Local reactions
- Pain or tenderness
- Redness
- Itching
- Swelling or temporary puffiness
- Warmth or firmness under the skin
Temporary swelling does not necessarily mean something went wrong. The fluid has been deliberately placed under the skin and needs time to be absorbed. Contact the healthcare team if a reaction becomes severe, continues for several days, spreads, or is accompanied by signs of infection.
Systemic side effects
Common whole-body reactions reported in clinical studies included headache, nausea, fatigue, diarrhea, and vomiting. Cough, joint discomfort, throat pain, dizziness, or general malaise may also occur.
Infusion reactions should be recorded even when they seem minor. A pattern may help the prescribing team determine whether the rate, site volume, needle length, hydration routine, or schedule should be reconsidered.
Serious Warnings and Emergency Symptoms
Blood clots
Cuvitru carries a boxed warning for thrombosis. Blood clots can occur even when a patient has no obvious risk factor. Risk may be higher in older adults and people with cardiovascular disease, a previous clot, prolonged immobility, increased blood viscosity, clotting disorders, an indwelling vascular catheter, or estrogen use.
Seek emergency care for sudden chest pain, unexplained shortness of breath, a rapid pulse, one-sided weakness or numbness, difficulty speaking, or pain, swelling, warmth, or discoloration in an arm or leg. Patients at increased risk should be adequately hydrated and treated using the minimum practical dose and rate.
Severe allergic reactions
Stop the infusion and obtain immediate medical help for hives, wheezing, chest tightness, faintness, swelling of the face or throat, or difficulty breathing or swallowing. A serious reaction can occur even after previous immune globulin treatments were tolerated.
Cuvitru contains trace amounts of IgA. It is contraindicated in IgA-deficient patients who have antibodies against IgA and a history of hypersensitivity to human immune globulin.
Kidney problems
Acute kidney dysfunction and kidney failure have occurred with immune globulin products. Cuvitru does not contain sucrose, an ingredient associated with higher kidney risk in some formulations, but monitoring may still be necessary.
Warning signs include reduced urination, sudden weight gain, swelling of the face or limbs, fluid retention, and shortness of breath. Risk may be greater in people with existing kidney disease, diabetes, sepsis, dehydration, paraproteinemia, advanced age, or use of medications that can damage the kidneys.
Aseptic meningitis syndrome
Aseptic meningitis can begin within several hours to two days after immune globulin treatment. Symptoms may include an intense headache, stiff neck, fever, sleepiness, light sensitivity, painful eye movements, nausea, and vomiting. These symptoms require prompt medical evaluation because infectious meningitis and other emergencies must be ruled out.
Hemolysis
Antibodies in immune globulin can occasionally cause the destruction of red blood cells. Contact a doctor promptly for dark urine, yellow skin or eyes, unusual fatigue, rapid heartbeat, shortness of breath, or pain in the abdomen or back.
Transfusion-related acute lung injury
TRALI is a rare but serious lung reaction that may develop within one to six hours after an infusion. Emergency symptoms include severe breathing difficulty, chest pain, fever, bluish lips or fingertips, and low oxygen levels.
Infectious-agent risk
Cuvitru is manufactured from donated human plasma. Donors and plasma are screened, and the manufacturing process includes multiple virus-removal and inactivation steps. These safeguards greatly reduce risk, but plasma-derived products cannot be guaranteed to have zero possibility of transmitting known, emerging, or theoretically transmissible agents.
Cuvitru Drug and Vaccine Interactions
Cuvitru is not known for a long catalog of conventional metabolic drug interactions. Its most important documented interaction involves live attenuated vaccines. Passively transferred antibodies may reduce the immune response to measles, mumps, rubella, or varicella vaccines.
The effect may last up to six months for mumps, rubella, and varicella vaccines and a year or longer for measles vaccine. Tell every vaccination provider that Cuvitru is being used so vaccine timing and expected effectiveness can be evaluated appropriately.
Patients should also provide a complete list of prescription drugs, over-the-counter medicines, vitamins, and supplements. Estrogen-containing products may add to clot risk, while nephrotoxic medications may require closer kidney monitoring.
Laboratory test interference
Passively transferred antibodies can cause misleading positive results on certain blood tests, including antiglobulin or Coombs testing. Cuvitru may also cause false-positive beta-D-glucan test results used during evaluations for fungal infections. Tell laboratory personnel and treating clinicians about recent infusions.
Cuvitru Pictures, Vial Sizes, and Appearance
Cuvitru is supplied as a clear liquid that may be colorless, pale yellow, or light brown. It should be free of visible particles. Do not use a vial if the liquid is cloudy, unusually discolored, frozen, or past its expiration date.
In the United States, single-dose vials are available in the following sizes:
| Vial volume | Amount of IgG | Concentration |
|---|---|---|
| 5 mL | 1 gram | 200 mg/mL |
| 10 mL | 2 grams | 200 mg/mL |
| 20 mL | 4 grams | 200 mg/mL |
| 40 mL | 8 grams | 200 mg/mL |
| 50 mL | 10 grams | 200 mg/mL |
The carton and vial label display the Cuvitru brand name, the words “Immune Globulin Subcutaneous (Human) 20%,” the volume, protein amount, lot number, expiration date, and single-dose designation. Product appearance alone should never be used to identify an unlabeled medication.
Storage and Handling
Cuvitru may be refrigerated at 36°F to 46°F for up to 36 months or stored at room temperature no higher than 77°F for up to 24 months, subject to the printed expiration date. Once moved to room-temperature storage, it should not be returned to the refrigerator.
Keep vials in the original carton to protect them from light. Do not freeze or shake the product. Frozen medication, partially used vials, and expired medication must be discarded according to instructions from the pharmacy or healthcare team.
Pregnancy, Breastfeeding, Children, and Older Adults
Human data are insufficient to determine whether Cuvitru creates a medication-related pregnancy risk. Immune globulins cross the placenta increasingly during later pregnancy. Treatment should be used during pregnancy when clearly indicated after the benefits and uncertainties have been discussed with the healthcare team.
There are also limited data regarding Cuvitru during breastfeeding. The mother’s clinical need, the benefits of breastfeeding, and potential effects on the infant should be considered together.
Cuvitru is approved for children age 2 and older. Clinical studies found generally similar safety and effectiveness in pediatric and adult participants, and no separate pediatric dose formula was required to reach intended IgG levels. Safety and effectiveness have not been established in children younger than 2.
Older adults may require closer monitoring for kidney dysfunction and thrombosis, particularly when they have cardiovascular conditions, limited mobility, dehydration, or other risk factors.
Experiences With Cuvitru: What Long-Term Treatment May Feel Like
Experiences with Cuvitru vary considerably, but the early learning period is often the most demanding. The first home-infusion setup may feel like someone emptied a small medical-supply closet onto the kitchen table: vials, syringes, tubing, needles, dressings, alcohol wipes, a pump, and a sharps container all competing for attention. A written checklist can turn that collection from intimidating clutter into a repeatable routine.
Many patients become faster and more confident after several supervised sessions. They learn where the most comfortable infusion sites are, how far apart to place them, which clothing provides easy access, and how to secure the tubing without accidentally creating an elaborate knot. Caregivers often discover that organizing supplies in treatment order reduces mistakes and keeps the process calm.
Temporary swelling at an infusion site is one of the most commonly discussed experiences. A small raised area can develop as the solution enters the tissue, then gradually flatten as it is absorbed. Some people experience itching, warmth, redness, or soreness. Rotating sites, allowing alcohol to dry fully, confirming needle placement, and discussing site volume with the clinical team may improve comfort. Persistent, unusually painful, hot, or spreading reactions deserve medical attention rather than optimistic guessing.
Scheduling is another major adjustment. A weekly infusion may be easier to remember when connected to a stable routine, such as the same evening and television program each week. Other patients prefer smaller, more frequent doses or an every-other-week schedule. Flexibility is useful only when treatment remains consistent, so calendars, alarms, and infusion logs can be surprisingly powerful medical accessories.
Patients transitioning from IVIG sometimes appreciate avoiding difficult vein access, travel to an infusion facility, and the pronounced rise-and-fall pattern they associated with monthly treatment. Subcutaneous dosing produces steadier IgG exposure, but it also transfers more responsibility to the patient or caregiver. Supplies must be stored correctly, orders must arrive on time, and reactions must be documented accurately.
Hydration is frequently emphasized, especially for people with kidney or clotting risks. Patients may plan fluids earlier in the day rather than attempting to drink an entire reservoir five minutes before starting. Comfortable clothing, a clean workspace, entertainment, and easy access to a phone can also make an infusion session feel less clinical.
Some people experience headache, fatigue, nausea, or digestive symptoms after treatment. Keeping a detailed diary can reveal whether symptoms follow a particular rate, dose schedule, site pattern, or hydration level. The healthcare team can then assess whether changes are appropriate. Patients should never independently accelerate an infusion simply because last week’s session went smoothly; tolerability can change, and “faster” is not a competitive sport.
The emotional experience matters as well. Self-infusion can initially create anxiety, particularly for children, needle-sensitive adults, or caregivers worried about doing something incorrectly. Repeated training, demonstrations, written instructions, and access to the specialty pharmacy or clinical team can build confidence. Families may use distraction, predictable routines, or age-appropriate rewards while still teaching the child to report discomfort honestly.
Over time, the most successful routine is usually not the most ambitious one. It is the schedule that maintains protective IgG levels, controls infections, fits daily life, and remains comfortable enough to follow consistently. Regular follow-up remains essential because weight, health conditions, infection frequency, laboratory results, pregnancy, new medications, or travel plans may change the treatment strategy.
Conclusion
Cuvitru is a concentrated 20% subcutaneous IgG replacement therapy for adults and children age 2 and older with primary humoral immunodeficiency. Its flexible schedule and potential for trained home administration can make lifelong immune globulin treatment more manageable, but convenience does not eliminate risk.
Common reactions include infusion-site discomfort, redness, itching, headache, nausea, fatigue, diarrhea, and vomiting. Serious concerns include blood clots, anaphylaxis, kidney injury, aseptic meningitis, hemolysis, and acute lung injury. Safe use depends on individualized dosing, careful training, consistent infusions, proper storage, laboratory monitoring when indicated, and prompt attention to warning symptoms.
